Protein Allostery in Rational Drug Design

被引:8
|
作者
Kinoshita, Takayoshi [1 ]
机构
[1] Osaka Prefecture Univ, Grad Sch Sci, Sakai, Osaka, Japan
来源
关键词
Protein kinase; Allosteric inhibitor; Structure-based drug discovery; High selectivity; CRYSTAL-STRUCTURES; KINASE INHIBITORS; BINDING; IDENTIFICATION; TARGET; POTENT; SITE; SELECTIVITY; MECHANISM; CK2-ALPHA;
D O I
10.1007/978-981-13-8719-7_3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This chapter focuses on protein kinases that transfer the phosphate group of ATP to the hydroxyl group of a substrate protein. Five hundred eighteen human protein kinases are classified into serine/threonine kinases and tyrosine kinases and individually or synergistically transduce physiologic stimuli into cell to promote cell proliferation or apoptosis, etc. Protein kinases are identified as drug targets because dysfunction of kinases leads to severe diseases such as cancers and autoimmune diseases. A large number of the crystal structures of the protein kinase inhibitor complex are available in Protein Data Bank and facilitated the drug discovery targeting protein kinases. The protein kinase inhibitors are classified into categories, Type-I, Type-II, Type-III, Type-IV, and Type-V, and as a separate class, covalent-type inhibitors. In any type, a protein kinase inhibitor bound to the allosteric region is advantageous in terms of selectivity compared to the traditional ATP-competitive one. In the following sections, the successful and promising examples of the partially or fully allosteric protein kinase inhibitors are illustrated in the following pages.
引用
收藏
页码:45 / 64
页数:20
相关论文
共 50 条
  • [1] The value of protein allostery in rational anticancer drug design: an update
    Nussinov, Ruth
    Jang, Hyunbum
    EXPERT OPINION ON DRUG DISCOVERY, 2024, 19 (09) : 1071 - 1085
  • [2] Rational design of protein switches based on the ensemble model of allostery
    Choi, Jay
    Laurent, Abigail
    Hilser, Vincent
    Ostermeier, Marc
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [3] Editorial: Understanding Protein Dynamics, Binding and Allostery for Drug Design
    Hu, Guang
    Doruker, Pemra
    Li, Hongchun
    Demet Akten, Ebru
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
  • [4] LIGAND PROTEIN DOCKING AND RATIONAL DRUG DESIGN
    LYBRAND, TP
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 1995, 5 (02) : 224 - 228
  • [5] Protein Allostery in Drug Discovery Preface
    Zhang, Jian
    PROTEIN ALLOSTERY IN DRUG DISCOVERY, 2019, 1163 : V - V
  • [6] Rational drug design via intrinsically disordered protein
    Cheng, Yugong
    LeGall, Tanguy
    Oldfield, Christopher J.
    Mueller, James P.
    Van, Ya-Yue J.
    Romero, Pedro
    Cortese, Marc S.
    Uversky, Vladimir N.
    Dunker, A. Keith
    TRENDS IN BIOTECHNOLOGY, 2006, 24 (10) : 435 - 442
  • [7] Membrane Protein Structures for Rational Antimicrobial Drug Design
    Walden, Patricia M.
    McMahon, Roisin M.
    Archbold, Julia K.
    AUSTRALIAN JOURNAL OF CHEMISTRY, 2014, 67 (12) : 1724 - 1731
  • [8] Protein crystallization in drug design: towards a rational approach
    Derewenda, Zygmunt S.
    EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (10) : 1329 - 1340
  • [9] Harnessing Proteasome Dynamics and Allostery in Drug Design
    Gaczynska, Maria
    Osmulski, Pawel A.
    ANTIOXIDANTS & REDOX SIGNALING, 2014, 21 (17) : 2286 - 2301
  • [10] Cell biology - Lessons in rational drug design for protein kinases
    Ahn, NG
    Resing, KA
    SCIENCE, 2005, 308 (5726) : 1266 - 1267